← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $618B	3,315	-12	-0.4%	$292B
2	2 Pfizer PFE $170B	2,806	+71	+3%	$160B
3	3 AbbVie ABBV $510B	2,657	-20	-0.7%	$127B
4	4 Merck MRK $369B	2,649	-26	-1%	$139B
5	5 Bristol-Myers Squibb BMY $125B	2,294	-77	-3%	$96.6B
6	6 Amgen AMGN $239B	2,134	-63	-3%	$90.3B
7	7 Gilead Sciences GILD $198B	1,564	+18	+1%	$70.1B
8	8 Novartis NVS $288B	1,081	-39	-3%	$18B
9	9 Regeneron Pharmaceuticals REGN $83B	1,019	+47	+5%	$54.5B
10	10 AstraZeneca AZN $261B	909	+137	+18%	$31.1B
11	11 GSK GSK $98.9B	793	-7	-0.9%	$12.4B
12	12 DELISTED Exact Sciences EXAS	602	-23	-4%	$15.1B
13	13 Incyte INCY $23.1B	494	-29	-6%	$14B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	483	+6	+1%	$27.9B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	455	-50	-10%	$7.43B
16	16 Guardant Health GH $22.1B	374	-43	-10%	$11.8B
17	17 Natera NTRA $57.9B	350	+8	+2%	$10.2B
18	18 Exelixis EXEL $15.5B	340	-5	-1%	$5.63B
19	19 BioNTech BNTX $22.7B	336	+52	+18%	$10B
20	20 Halozyme HALO $13.8B	325	+10	+3%	$5.29B
21	21 NeoGenomics NEO $2.2B	324	+13	+4%	$5.58B
22	22 Takeda Pharmaceutical TAK $63B	293	-12	-4%	$1.51B
23	23 DELISTED Blueprint Medicines BPMC	288	+7	+2%	$6.13B
24	24 Fate Therapeutics FATE $230M	265	-7	-3%	$5.67B
25	25 Qiagen QGEN $9.58B	265	+7	+3%	$6.77B